Full Title
A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based ChemotherapyPurpose
Researchers are seeking the best dose of raludotatug deruxtecan (R-DXd) for people with ovarian cancer when given with standard chemotherapy. The people in this study have ovarian cancer that came back after chemotherapy that included a platinum-containing drug.
R-DXd is a type of drug called an antibody-drug conjugate. The antibody binds to a protein on cancer cells called CDH6. The linked drug enters these cells and kills them, with reduced risk of harming other cells.
If your ovarian cancer came back 6 months or more after platinum-containing chemotherapy, you will get R-DXd with paclitaxel. If your ovarian cancer came back within 6 months after platinum-containing chemotherapy, you will get R-DXd with bevacizumab.
Who Can Join
To join this study, there are a few conditions. You must:
- Have ovarian cancer that came back after platinum-based chemotherapy.
- Have recovered from the serious side effects of prior treatment before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Paul Johannet’s office at 646-888-5327.